Novo Ventures has stepped up to lead a $49 million round for San Diego-based Thesan Pharmaceuticals, which is developing new dermatology drugs for conditions like acne and atopic dermatitis.
On the same day it announced a $55 million E round, California biotech Versartis filed to go public in an $80 million IPO, planning to use its fast-growing bank account to get a promising orphan therapy through late-stage trials.
Swiss biotech Novimmune has closed a $66 million B round to bankroll its broad pipeline of monoclonal antibodies, and one of the company's lead investors told a local newspaper that it's considering going public to further finance its projects.
Tokyo drug developer RegImmune has banked $9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform.
I've been in the U.K. for a few days now, grabbing some meetings along the way after discussing valuations in biotechnology with a group of One Nucleus members at The Babraham Institute near Cambridge. And I've been thinking about this question a lot this week.
Third Rock Ventures has cut the ribbon on its latest startup, pledging $45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising platform for central nervous system treatments.
In the 10 months since Mary Szela took charge of Melinta Therapeutics--the antibiotics developer once known as Rib-X--the CEO has built up an experienced team of R&D executives. Now she also has the money needed to wrap an ambitious late-stage program for their lead product while preparing to usher a new set of assets into the clinic.
North Carolina's Argos Therapeutics raked in $45 million in a below-its-range Wall Street debut, sticking a so-so endcap on an otherwise colossal week for biotech IPOs in which drug developers banked more than $500 million.
Clarus Ventures is raising $375 million for a third fund, building up its war chest to bankroll new bets on drug and med tech outfits.
A fledgling biotech in Norway's notable cancer drug cluster has garnered about $12.5 million to back its early-stage efforts on a new therapy for acute myeloid leukemia and non-small cell lung cancer.